Inspire Medical Systems Reports Strong Preliminary Q4 & FY2025 Revenue, Issues Positive 2026 Guidance, and Appoints New CFO
INSP sits 37% above its 52-week low of $70.77.
Summary
Inspire Medical Systems reported strong preliminary revenue for Q4 and full-year 2025, provided positive 2026 guidance, and announced the appointment of Matthew J. Osberg as its new Chief Financial Officer.
Key Events · Earnings and Guidance · INSP
-
Strong Preliminary 2025 Revenue
Reported preliminary unaudited revenue for Q4 2025 in the range of $268.9 million to $269.1 million (approx. 12% increase year-over-year) and full year 2025 revenue between $911.8 million and $912.0 million (approx. 14% increase year-over-year).
-
Positive 2026 Revenue Guidance
Provided initial full year 2026 revenue guidance of $1,003 million to $1,013 million, representing a 10% to 11% increase over full year 2025.
-
New Chief Financial Officer Appointed
Matthew J. Osberg was appointed as Executive Vice President and Chief Financial Officer, effective after the 2025 10-K filing. Mr. Osberg brings extensive experience from previous CFO roles at Apogee Enterprises, Inc. and Helen of Troy Limited.
-
CFO Compensation Package
Mr. Osberg's compensation includes an annual base salary of $650,000, a target annual cash bonus of 70% of base salary, a $600,000 cash sign-on bonus, and equity awards (PSUs and RSUs) each valued at $1,500,000.
Analysis · INSP · Industrial Applications And Services
Inspire Medical Systems announced robust preliminary revenue figures for the fourth quarter and full year 2025, indicating strong execution and significant momentum. The company also provided initial full-year 2026 revenue guidance projecting continued growth. This financial update, coupled with the appointment of an experienced Chief Financial Officer, Matthew J. Osberg, from other public companies, signals stability and a positive outlook for the company's financial leadership and future growth trajectory. The CEO's comments highlight confidence in the company's performance and the positive impact of recent product launches and reimbursement developments.
At the time of this filing, INSP was trading at $96.93 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $70.77 to $211.99. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.